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ABSTRACT: The DOT1L lysine methyltransferase has
emerged as a validated therapeutic target in MLL-rearranged
(MLLr) acute leukemias. Although S-adenosylmethionine
competitive inhibitors have demonstrated pharmacological
proof-of-principle inMLLr-leukemia, these compounds require
further optimization to improve cellular potency and
pharmacokinetic stability. Limiting DOT1L inhibitor discovery
and ligand optimization have been complex biochemical
methods often using radionucleotides and cellular methods
requiring prolonged culture. We therefore developed a new
suite of assay technologies that allows comparative assessment
of chemical tools for DOT1L in a miniaturized format. Coupling these assays with structural information, we developed new
insights into DOT1L ligand binding and identiﬁed several functionalized probes with increased cellular potency (IC50 values ∼10
nM) and excellent selectivity for DOT1L. Together these assay technologies deﬁne a platform capability for discovery and
optimization of small-molecule DOT1L inhibitors.
Mixed-Lineage Leukemia (MLL) gene rearrangements occur in
5−10% of all acute leukemia patients and in greater than 70%
of infants with acute lymphoblastic leukemia (ALL). The
presence of the rearrangement portends a poor prognosis,
despite aggressive therapy with signiﬁcant associated morbid-
ity.1 Cooperation between speciﬁc chromatin-modifying
complexes and MLL-rearranged gene products deﬁnes disease
pathogenesis and has prompted eﬀorts to target modulators of
chromatin structure and function in this cancer.2,3
MLL is a member of the Trithorax family of proteins and
functions as a histone lysine methyltransferase (KMTase).1
During development, MLL catalyzes trimethylation of lysine 4
on histone 3 from the methyl donor S-adenosylmethionine
(SAM) at homeobox genes, promoting their expression. In
MLL-rearranged leukemia, however, the SET domain respon-
sible for KMTase activity is uniformly lost with translocation
and replaced by one of more 70 known fusion partners.3 Many
of these fusion partners recruit DOT1L, which is the only
known methyltransferase responsible for the mono-, di-, and
trimethylation of lysine 79 of histone 3 (H3K79). H3K79
methylation is associated with most actively transcribed genes
and marks regions of elongating RNA Pol II typically within the
ﬁrst intron of gene bodies.4 The recruitment of DOT1L by
MLL fusion partners to developmental MLL-target genes
results in aberrant hypermethylation of H3K79 at these loci,
contributing to leukemogenesis by inappropriately sustained
gene expression, namely at the HOXA locus.5−8
The therapeutic signiﬁcance of DOT1L in established MLL-
rearranged leukemia has been validated by genetic and chemical
genetic approaches. Conditional inactivation of Dot1L in MLL-
AF9 (and AF6 and AF10) leukemia models results in
diminished H3K79 methylation and prolonged survival.6,9−12
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Recently, SAM-competitive small-molecule inhibitors of
DOT1L have been developed, ﬁrst reported in 2011,13 and
further characterized biochemically and structurally by our
group in collaboration with Professor Cheryl Arrowsmith.14
Structurally, these SAM mimetics featured high potency and
selectivity for DOT1L. However, the cellular activity of these
compounds is rather low in potency relative to the
extraordinary subnanomolar binding potency in homogeneous
assays in vitro. Notably, the antileukemic eﬀect of DOT1L
inhibition requires 10−14 days of continuous dosing at high
(1−3 μM) concentrations in cell culture models using current
inhibitors.14−19 In animal studies, this translates to a modest
beneﬁt in survival while requiring high doses through
continuous osmotic subcutaneous infusion.13,15 Further opti-
mization of DOT1L inhibitors is therefore needed.
To date, development of structurally divergent DOT1L
inhibitors has been slow in the broader epigenetics community,
perhaps relating to the challenges in biochemistry and cell
biology platforms which underlie ligand discovery and
optimization. Thus far, biochemical assays of DOT1L use
radioligands and often require specialized synthetic or highly
puriﬁed histone particles as substrates. Additionally, the
ubiquitinylation of nucleosomes strongly inﬂuences DOT1L
activity and poses diﬃculties to ligand discovery.20 The delayed
cellular eﬀects of DOT1L inhibition challenge the miniatur-
ization of cell-based measures of compound potency. Simple
dose-ranging comparisons have proven time-consuming and
low-throughput. We therefore identiﬁed an opportunity to
create a facile discovery platform enabling the characterization
of existing DOT1L inhibitors, and the preparation of new
compounds with improved properties. Herein, we report the
development of tagged DOT1L ligands used in robust and
miniaturized biochemical assays, as well as a high-throughput,
high-content assay system that reports on pharmacodynamic
H3K79 methylation abundance in short incubation windows.
Together, these three orthogonal assays have deﬁned a platform
capable of discovering and optimizing novel DOT1L inhibitors.
■ RESULTS AND DISCUSSION
Toward the development of DOT1L chemical probes, we
chose a SAM-competitive inhibitor from our laboratory
(FED1) as a suitable starting point to develop assay ligands
for DOT1L (Figure 1a). FED1 is a near chemical derivative of
EPZ004777 that features a more eﬃcient and high-yielding
synthesis.14 Additionally, FED1 has a modestly reduced binding
potency for DOT1L that was postulated to improve utility in
competition binding assay development across a broad range of
inhibitors. Given the extended residence times of DOT1L
inhibitors (EPZ004777 Koff = 9.29 × 10
−4 s−1 and FED1 Koff =
2.20 × 10−3 s−1),14 a less potent inhibitor such as FED1 may
provide the opportunity to discover weaker initial assay
positives in high-throughput screening. The crystal structure
of FED1 shows a binding mode similar to EPZ004777, with
the tert-butyl phenyl urea motif further extending the binding
Figure 1. Design and characterization of chemical probes of DOT1L. (a) Structures of EPZ00477713 and FED1.14 (b) Structures of biotinylated (1)
and FITC-labeled (2) FED1 attached via a linker to the N6 position of the base. (c) Isothermal calorimetry analysis of 1 demonstrating strong 1:1
binding with DOT1L. (d) Binding of 1 to DOT1L demonstrates linker exposure and a similar binding mode to that of FED1. (e) Detailed ligand-
interaction diagram of 1 demonstrating new hydrogen bond formation. (f) Inhibition of H3K79me2 by indicated DOT1L inhibitors (10 uM) in
MV4;11 cells treated for 4 days. (g) DOT1L probe treatment results in inhibition of MV4;11 cell growth over time.
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pocket compared to SAM (Figure S1a, PDB: 4ER0).14 While
most of the molecule is deeply obscured in the binding pocket
and inaccessible to solvent, the more open position of the
nucleotide base suggested a tolerance for further chemical
substitution. We postulated that modiﬁcation on the N6
position of the FED1 adenine would not interfere with the
activity of the molecule, allowing the installation of features
with functional utility (e.g., retrievable chemical linkers and
ﬂuorophores).
We synthesized two probes (Supporting Information
Schemes 1 and 2), 1 with polyethylene glycol (PEG) linked
biotin and 2 with a thiourea-coupled ﬂuorescein (FITC)
(Figure 1b). The binding aﬃnities of these two modiﬁed
inhibitors were conﬁrmed by isothermal titration calorimetry
and are comparable to the parent compound (Figure 1c and
Figure S1b). The apparent potency of 1 was also similar to the
parent compound by diﬀerential scanning ﬂuorimetry (Figure
S1d). The crystal structure of 1 with DOT1L was then
obtained. Ligand 1 bound to the SAM pocket as expected, with
the structured features of the linker protruding out toward the
solvent. The lack of atomic density for the remaining PEG and
biotin features likely reﬂects unrestricted mobility in solvent
(Figure 1d). The ligand-interaction diagram further conﬁrmed
that DOT1L binds to 1 and FED1 in a manner dictated by
common determinants of molecular recognition (Figure 1e,
Figure S1c). The amide bond of the linker unit also formed a
hydrogen bond with a structured water molecule, which may
contribute to preservation of the ligand binding activity. Cell
permeability was conﬁrmed by immunoblot for the H3K79
dimethyl (H3K79me2) histone mark, which was eﬃciently
depleted by both ligands (Figure 1f). As then expected, both
compounds inhibited cell proliferation comparably to
EPZ004777 after 10−14 days (Figure 1g).
Figure 2. Development of nonradiometric biochemical and cellular assays for DOT1L. (a−c) AlphaScreen proximity bead-based assay
demonstrating adaptability to high-throughput screening (Z′ calculated by 1 − ((3σFED1 + σDMSO)/absolute value(μFED1 − μDMSO)), and expected
comparable potency diﬀerentiation of known inhibitors. (d−f) Fluorescence polarization assay demonstrating signiﬁcant assay robustness (Z′
calculated with above formula) and separation of weak DOT1L inhibitors (SAH) from more potent compounds (FED1 and EPZ004777). (g−i)
High-content imaging assay evaluating H3K79me2 abundance by immunoﬂuorescence in A431 cells after 4 days of indicated DOT1L inhibitors,
with diminished H3K79me2 compared to DMSO. Assay is robust (Z′ calculated as above) and reports cellular EC50. Biochemical assays were
performed in duplicate, and high-content assays were performed as four replicates.
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With these validated ligands in hand, we next developed
orthogonal biochemical assays capable of detecting small
molecule binding to puriﬁed, recombinant human DOT1L
protein. The ﬁrst assay utilizes 1 and employs a nanomaterial
proximity assay (AlphaScreen, PerkinElmer; Figure 2a−c). The
biotin on 1 recruits a streptavidin-coated donor bead, while the
FED1 portion of the molecule recruits a nickel-coated receptor
bead via binding to the recombinant HIS6-DOT1L methyl-
transferase domain. Illumination of the donor bead releases
singlet oxygen, which diﬀuses to activate in situ synthesis of a
chemiluminescent lanthanide within the acceptor bead only
when the two are in close proximity, here dependent on the
DOT1L−ligand interaction. Displacement of 1 from DOT1L
disrupts the proximity of the two beads and diminishes
chemiluminescence. Finally, we have miniaturized the assay to
microtiter plate format (384-well) and improved robustness
compatible with high-throughput screening (Z′ = 0.78). Using
a set of resynthesized DOT1L chemical tools, we conﬁrmed
faithful utility in comparative ligand potency determination
(IC50 for EPZ004777 5.3 nM, FED1 22.4 nM, SAH 1299 nM).
Next, a ﬂuorescence polarization (FP) assay was developed
to monitor binding of inhibitors to DOT1L using the
ﬂuorescent probe 2 (Figure 2d−f). After excitation with
plane-polarized light, binding of 2 to DOT1L increases
anisotropy of the bound state relative to free 2. Therefore,
displacement of noncovalently bound 2 from DOT1L by a
competitive ligand leads to a decrease in detectable signal. This
FP assay has proven amenable to high-throughput screening
(Z′ = 0.91) and accurately discriminates compounds in our
reference set by relative potencies. In our experience to date,
the FP assay is more suitable to HTS than the bead-based
proximity assay owing to false-positives that are assay speciﬁc
(nickel chelation, biotin mimetics). Together, these two assays
are highly complementary in screening and lead optimization.
To support iterative development of DOT1L inhibitors using
a cellular assay capable of reporting on methyltransferase
function, we developed a high-content imaging assay to
measure global nuclear H3K79me2 with short-term compound
incubation (3−4 days; Figure 2g−i). The A431 epidermoid
carcinoma cell line was selected based on high basal
H3K79me2 and strong adherence, which tolerated the harsh
immunoﬁxation conditions required to detect staining of this
mark on the histone body. Cells were treated for 4 days with
the compound in 384-well plates and then assessed for
H3K79me2 using primary and secondary (ﬂuorescent-con-
jugated) antibodies. Using our reference compound set, the
Figure 3. Purine substitutions of adenosyl DOT1L inhibitors. (a) Synthetic scheme illustrating generation of focused library of hydrazine inhibitors,
modiﬁed oﬀ the N6 position. (b, c) Biochemical screening results of the library at four doses, with (d) cellular H3K79me2 screen at 20 uM
compared to FED1 (indicated in blue). (e) Structures of resynthesized assay positives. (f) Proﬁling table of validated assay positives compared to
FED1.
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dynamic range of this assay format proved capable of
supporting dose-ranging studies and correctly ranked the
cellular potency of all inhibitors: in comparative format,
EPZ004777 was more potent than FED1, and SAH was
ineﬀective at reducing H3K79 methylation levels in cell culture.
This cellular assay allows both the comparisons between
compounds to measure in-cell eﬃcacy and the evaluation of
multiple compounds simultaneously in dose−response. It is
also amenable to further evaluate any screening hits obtained
from the AlphaScreen and FP assays and could also be
employed as a primary assay for cell-based, high-throughput
screening (Z′ = 0.62).
To test the DOT1L discovery platform, we generated a small
focused library of compounds exploring the tolerability of
substitutions of the adenosine base using a highly parallel
chemistry we codeveloped to explore surface-recognition
features of organic ligands (hydrazine cap-scan technol-
ogy).21,22 Informed by the DOT1L-FED1 and DOT1L-1
crystal structures,18 we developed a focused library of N6-
substituted ligands. A hydrazine functional group was
introduced to the adenosine ring via a nine-step synthesis
starting from known compound 3 (Supplemental Scheme 3).
The hydrazine 4 then condensed with 90 divergent aldehydes/
ketones in 96-well format to generate the hydrazone library 5
(Figure 3a) without the need for further puriﬁcation. The facile
assembly of the library allowed rapid exploration of structure−
activity relationships (SAR) at N6, and the exercise provided
ﬁrm validation of the assay cascade. All analogues were
evaluated in both biochemical assays in four-point dose
response, followed by the H3K79me2 high content screening
at a single dose. Most members of the hydrazine library showed
high levels of activity in all three assays, suggesting that this site
Figure 4. Development of potent chlorinated DOT1L inhibitors. (a) Structures of 9, 10, and 11. (b−e) Evaluation of SAM-like derivatives by
biochemical assays demonstrating similar potency, and high content assay demonstrating increased potency of chlorinated inhibitors (10, 11) and
improvement of FED1 potency with substitution of a thiourea tail. Biochemical assays were run in duplicate and high-content assays in
quadruplicate. (9). (f) Immunoblot for H3K79me2 demonstrating improved DOT1L inhibition by 11 in MOLM-13 cells treated for 4 days (all at 1
uM). (g) 11 (10 uM) demonstrates speciﬁcity for H3K79me2 inhibition by immunoblot for histone methylation marks in MOLM-13 cells. (h)
HoxA9 and Meis1 mRNA in MV4;11 cells decreases with DOT1L inhibition (10 uM) in proportion to cellular IC50 after 7 days of treatment (RT-
PCR). (i) Inhibition of MV4;11 cell growth over time with DOT1L inhibitor treatment (10 uM) demonstrates correlation with HCS potency.
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is highly permissive for a wide range of chemical functionalities
(Figure 3b−d). Comparison of library activity in the two
biochemical assays demonstrated generally good agreement
between both assays (Figure S2). A group of outliers that were
highly active in only the bead-based assay were triaged as likely
assay-interference agents. Three of the hydrazones that showed
the most consistent activity between all assays were
resynthesized for retest with a 10-point, dose−response
curve; these three compounds contained nitrogenous hetero-
cyclic rings, including an indole (6), an imidazole (7), and a
pyridine (8; Figure 3e). While these three compounds are more
potent than the parent hydrazine 4, they had modestly weaker
biochemical activity than FED1 (Figure 3f). Although the
modiﬁcations explored in the focused library did not provide
large gains in potency, the study validated all assays in a high-
throughput format.
We then explored further features of the SAM-like core
structure. In addition to the N6 substitutions, we modiﬁed the
urea tail along with another location on the adenosine base.
The urea motif has also been further explored with generating a
small urea library (Supporting Information Scheme 5), and we
discovered introduction of the thiourea group to FED1
produced a 10-fold increase in cellular activity (9) without
signiﬁcantly changing biochemical activity. On the adenosine
base, we focused on the C7 position of the ring and discovered
that introduction of a chlorine group on the C7 position of the
deazaadenosine motif could generate a desirable interaction
with the nearby hydrophobic pocket (10), leading to an
increase in potency in all assays. By combining these two
beneﬁcial optimizations, we generated 11 with the introduction
of both C7-chlorine and thiourea (Figure 4a). 11 was more
potent as we expected in both the biochemical assays, and both
10 and 11 were more potent than EPZ004777 in the
H3K79me2 high-content assay (Figure 4b−e).
With the improved potency in the cellular assay, we then
conﬁrmed the relative potencies of these compounds by
immunoblotting for H3K79me2 in MLL cells (MOLM-13).
This was followed by evaluation of the selectivity of the
representative 11 to inhibit only the DOT1L methyltransferase
by immunoblotting for a number of histone methylation marks
mediated by other KMTases and an arginine methyltransferase.
The only mark aﬀected by these compounds is H3K79me2
(Figure 4f,g, Figure S3). We then further ensured the on-target
eﬀect of these compounds by assessing gene-expression
changes in MV4;11 cells. Decreased expression of both MLL-
target genes HOXA9 and MEIS1 was observed after 7 days of
incubation. The potency in gene expression correlated to eﬀects
on H3K79me2 reported by high-content screening, further
validating that the 4-day H3K79me2 measurement accurately
predicts on-target biological activity previously observed after
7−10 days of treatment (Figure 4h). As expected, these
measurements also correlated with an antiproliferative eﬀect in
treated MV4;11 cells (Figure 4i). Therefore, utilizing our novel
assay cascade and structural information, we developed
inhibitors of DOT1L with enhanced cellular activity and
maintained selectivity compared to previously reported
compounds.
Our approach to aﬃnity ligand design for assay development
was based on a structural understanding of the binding mode
between small molecule and target. Since the addition of the
handle on the small molecule does not impact its DOT1L
potency, the resultant probes 1 and 2 reported here can be used
as chemical tools for assay development and further
mechanistic studies of the DOT1L complex and its function
in MLL.23 The hydrazine library demonstrated the accom-
modation of DOT1L to large substituents oﬀ the base, but
potency was not maintained, perhaps from impurities in the
original screen. However, this site appears to be permissible for
future medicinal chemistry eﬀorts toward improving pharma-
cokinetics or compound stability. Further exploration of the
base and urea tail moiety, as accurately characterized by our
assay cascade, led to the identiﬁcation of more potent
compounds than EPZ004777 with improved cellular activity.
■ CONCLUSIONS
Together, these chemical biology tools for the study of DOT1L
provide a nimble platform for discovery chemistry. The label-
free biochemical assays and rapid cellular assay will be useful for
discovering both allosteric and direct SAM-competitive
DOT1L inhibitors, although substrate-competitive inhibitors
may be silent in these biochemical assays. The high content
assay, however, should be agnostic to the mode of inhibition. It
also has the potential to detect inhibitors of other proteins that
modulate DOT1L activity or the rate of H3K79me2 removal.
These tagged and potent inhibitors are openly available for use
to probe DOT1L biology. We hope this design principle will be
adapted to inhibitor discovery for other critical methyltrans-
ferases implicated in disease, including EHZ2 and MMSET.
■ METHODS
For protein expression and puriﬁcation, crystallization, data
collection and indexing, isothermal calorimetry, protein thermal
melt, cell culture, gene expression, and immunoblotting, please
see the Supporting Information.
DOT1L AlphaScreen Binding Assay. All reagents were
diluted in 50 mM HEPES, 150 mM NaCl, 0.5% BSA (w/v),
0.05% Tween20 (w/v), and pH 8.0 with 1 mM DTT added.
The ﬁnal concentration of His6-DOT1L was 80 nM, and that
of 1 was 40 nM. The addition of 10 uL of 2× this solution to
the plates (AlphaScreen plates, PerkinElmer #6005359) was
performed with a liquid handler. A total of 100 nL of
compounds was added by pin transfer using a Janus
Workststation (PerkinElmer, USA). After a brief centrifugation,
plates were incubated at RT for 30 min. A 2× solution of beads
was made such the ﬁnal concentrations of both the acceptor
and donor beads were 25 μg mL−1. A total of 10 μL of this
solution was added to the plate, and after centrifugation and 20
min incubation, plates were read on the Envision 2104 plate
reader (PerkinElmer, USA). Dose response data normalized to
DMSO controls.
DOT1L Fluorescence Polarization Assay. All reagents
were diluted in PBS with 1 mM DTT freshly added. A total of 5
μL of DOT1L solution (ﬁnal concentration 1 μM) was added
to 384-well plates (Thermo Scientiﬁc 262260) with a Biotek
EL406 liquid handler. A total of 100 nL of compounds from
stock plates was added by pin transfer using a Janus
Workststation. After a brief centrifugation, plates were
incubated at RT for 30 min. A total of 5 μL of a 2× solution
of 2 (ﬁnal concentration 10 nM) was added, and the plate was
brieﬂy centrifuged. After 30 min incubation at RT, plates were
read on the Envision 2104 plate reader. Flatﬁeld and
polarization calculations were performed by manufacturer’s
protocol, and anisotropy was calculated based on the formula
2P/3 − P in which P = polarization. Results were normalized to
DMSO controls.
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High Content Imaging Assay. A431 cells were plated at
1000 cells/well in 50 μL in 384-well clear bottom plates
(Corning 3712) and incubated for 1 h at RT. Compounds were
added using a Janus Workstation and incubated for 4 days.
After this, cells were ﬁxed in 3.7% formaldehyde in PBS at RT
×10 min. After two rinses with blocking solution (1% BSA in
PBS), 1% SDS in PBS was added for 2 min. After one wash,
cells were incubated with blocking solution at RT ×30 min.
Cells were then incubated for either 1 h at RT or overnight at 4
°C in 10 μL of primary antibody for H3K79me2 (ab3594) at a
1:500 dilution in blocking solution. After rinsing with blocking
solution, cells were then incubated for 1 h at RT in 10 μL of
secondary antibody (Invitrogen A-21244) and nuclear staining
(Invitrogen H3570) solution at 1:1000 dilution in blocking
solution. Cells were washed twice, after which 50 μL of PBS
was added to each well. Images were acquired on a high content
screening microscope (ImageXpress Micro, Molecular Devi-
ces), and image analysis (MetaXpress3.0, Molecular Devices)
was performed to obtain an average H3K79me2 signal per cell.
Dose response data (normalized to DMSO) were generated
(Graphpad Prism) by normalization of maximum and
minimum H3K79me2.
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